InvestorsHub Logo
Followers 93
Posts 21466
Boards Moderated 0
Alias Born 06/07/2011

Re: PINKribbon post# 123887

Monday, 05/18/2020 3:22:11 PM

Monday, May 18, 2020 3:22:11 PM

Post# of 144813
New investors, many times it’s been said

and will continued to be said...

that PharmaCyte’s PI, world renowned oncologist, Dr. Manuel Hidalgo, never “presents” PharmaCyte’s CiaB PC therapy as being an “emerging” therapy in pancreatic cancer medicine



Because he doesn't.

Well, that’s simply because he needs to see consistent findings or evidence first



Yet it doesn't prevent Hidalgo to throw out "IFs", and "could" in a Kenny PR pump.

Neither has Hidalgo required CT results when discussing Emerging Therapies. In a 2018 article discussing the role of stem cells in pancreatic cancer, he referenced it as a potential emerging area:

Since CSCs are resistant to traditional therapies including gemcitabine chemotherapy and radiotherapy [61,62], targeting the signaling pathways (Hedgehog, NANOG, STAT3) that drive cancer cell stemness represent a strategy against CSCs.



No drugs were mentioned. None were present at the time in CTs. He frequently mentions various targeted pathways, and immunotherapy targets, as emerging therapies. But he does not mention CIABs or other local drug delivery as "emerging". No need to mention an antiquated therapy idea from 20 yrs ago. DOA.

It has NOTHING to do with his credibility.



Neither does acting as a paid consultant. Stating a couple of generalities in Kenny PR pumps, before collecting his fee.

There you have it...cut and dry.



Yep, complete with the important "IF"

If this endpoint is met,



Is Hidalgo suppose to trash the Kenny Wonder Treatment in a Kenny PR pump, and then stick out his paw to be paid? Or did he suddenly have a memory lapse that Ifosfamide has previously failed in 2nd line patients? So which one is it?

IND submission underway!



Slow internet connection to the FDA?

Patience



Another 6 yrs ought to do ... sumpthin.

The Jewel of the Mind is Colored with the Hue of what it Imagines

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News